Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06144645 · ClinicalTrials.gov registry record · Phase 3

A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS

A Phase 3 study of Prader-Willi Syndrome, sponsored by Foundation for Prader-Willi Research.

Recruiting
Registry status
Phase 3
Development phase
102
Enrollment target
18
Study locations

NCT06144645: Recruiting Phase 3 study of Prader-Willi Syndrome, sponsored by Foundation for Prader-Willi Research.

NCT06144645 is a Phase 3 study of Prader-Willi Syndrome that is actively recruiting participants, run by Foundation for Prader-Willi Research. The registered enrollment target is 102 participants, above the 65-participant average among 16 other Prader-Willi Syndrome trials with a reported enrollment target (57% higher). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06144645, a Phase 3 study of Prader-Willi Syndrome, is actively recruiting participants, sponsored by Foundation for Prader-Willi Research.

RECRUITING
Registry status
Phase 3
Development phase
102 participants
Enrollment target
18
Study locations

Study Summary

The goal of the VNS4PWS clinical study is to test the efficacy, safety, and acceptability of transcutaneous vagus nerve stimulation (tVNS) treatment in people with PWS.

Primary Outcome

Frequency, severity, and seriousness of adverse events during the study.

Conditions Studied

Interventions

  • DEVICE tVNS, intermittent stimulation
  • DEVICE tVNS, continuous stimulation

Study Locations (18)

New York

  • Maimonides Medical Center - Brooklyn
  • NYU Langone Health - Garden City
  • Montefiore Medical Center and Albert Einstein College of Medicine - The Bronx

California

  • Stanford University - Palo Alto
  • Rady Children's Hospital San Diego - San Diego

Georgia

  • Emory University - Atlanta
  • Rare Disease Research - Atlanta

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland
  • Nationwide Children's Hospital - Columbus

Colorado

  • Children's Hospital Colorado - Aurora

Iowa

  • University of Iowa - Iowa City

Maryland

  • Johns Hopkins Hospital - Baltimore

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2024-01-08
Est. Completion 2027-12-01
Phase Phase 3

What NCT06144645 shows while recruiting

NCT06144645 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, above the 65-participant average among 16 other Prader-Willi Syndrome trials with a reported enrollment target (57% higher).

The record links to 1 condition, with Prader-Willi Syndrome appearing as the primary indexed condition, and to 2 interventions - of which tVNS, intermittent stimulation is the first listed.

NCT06144645 lists 18 locations in 13 states (New York, California, Georgia).

Frequently Asked Questions

What is clinical trial NCT06144645 about?

NCT06144645 is a clinical study titled "A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS". The goal of the VNS4PWS clinical study is to test the efficacy, safety, and acceptability of transcutaneous vagus nerve stimulation (tVNS) treatment in people with PWS.

What is the current status of trial NCT06144645?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 102 participants. The study started on 2024-01-08. Estimated completion is 2027-12-01.

What conditions does trial NCT06144645 study?

This clinical trial studies the following conditions: Prader-Willi Syndrome.

What interventions are being tested in trial NCT06144645?

The interventions under investigation include: tVNS, intermittent stimulation (DEVICE), tVNS, continuous stimulation (DEVICE).

Who is sponsoring clinical trial NCT06144645?

This trial is sponsored by Foundation for Prader-Willi Research, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06144645 being conducted?

This trial has 18 study locations across California, Colorado, Georgia, Iowa, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prader-Willi Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06144645's enrollment target sits among peer trials

102 4th of 16 higher than 13 of 16 other Prader-Willi Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prader-Willi Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03704662 · 102 participants · NA

    Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

  • NCT04174742 · 102 participants

    Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

  • NCT04275362 · 102 participants

    Gait Analysis of a Lateral-Pivot Design Total Knee Replacement

  • NCT04541082 · 102 participants · Phase 1

    Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06144645, the US trial registry maintained by the National Library of Medicine. NCT06144645 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.